摘要
目的探讨中药汤剂辅助甲氨蝶呤治疗未破裂型输卵管妊娠患者的有效性及安全性.方法按照随机数字法将2017年1月至2018年3月本院妇产科收治的70例未破裂型输卵管妊娠患者分为对照组与研究组,每组35例.对照组患者给予甲氨蝶呤治疗,1mg/kg,1次/d;研究组患者在对照组的治疗上加用中药汤剂,每日1剂;均持续治疗2周,随访3个月.比较两组临床疗效、人绒毛膜促性腺激素（β-HCG）转阴所需时间、附件包块完全吸收时间及治疗前后血清β-HCG水平、中医证候总积分及附件包块直径,观察不良反应发生情况.结果研究组的总有效率明显高于对照组（94.29%比82.86%,χ2=5.164,P=0.035）.研究组β-HCG转阴所需时间、附件包块完全吸收时间明显短于对照组[（27.56±8.01）d比（35.24±9.62）d,t=2.847,P=0.013;（35.44±13.28）d比（41.36±16.20）d,t=2.492,P=0.022].治疗后,两组血清β-HCG水平、中医证候总积分及附件包块直径均明显降低（均P〈0.05）;研究组血清β-HCG水平、中医证候总积分及附件包块直径均明显低于对照组[（351.46±102.53）U/L比（478.96±142.71）U/L,t=2.660,P=0.017;（5.72±1.93）分比（7.24±1.85）分,t=2.157,P=0.031;（0.58±0.06）cm比（1.04±0.08）cm,t=2.244,P=0.029];研究组不良反应发生率明显低于对照组（8.57%比17.14%,χ2=5.637,P=0.030）.结论中药汤剂辅助甲氨蝶呤治疗未破裂型输卵管妊娠起到协同增效的作用,能够迅速降低血清β-HCG水平及促进附件包块吸收,减少不良反应.
Objective To explore the effectiveness and safety of traditional Chinese medicine decoction adjuvant with methotrexate in the treatment of patients with unruptured tubal pregnancy. Methods 70 patients with unruptured tubal pregnancy treated at the department of gynaecology and obstetrics of our hospital from January, 2017 to March, 2018 were divided into a control group and a research group according to random number table, 35 cases for each group. The control group were treated with methotrexate, 1 mg/kg, once per day; in addition, and the research group were treated with traditional Chinese medicine decoction 1 agent per day. Both groups were treated for two weeks and followed up for three months. The clinical efficacy, clearance time of human chorionic gonadotropin（β-HCG）, and complete absorption time of adnexal mass were compared between two groups. The serum level of β-HCG, total TCM syndrome score, and diameter of adnexal mass were compared between two groups before and after treatment. The adverse reactions were observed. Results The total effective rate was significantly higher in the research group than that in control group （94.29% vs. 82.86%, χ2=5.164, P=0.035）. The clearance time of β-HCG and complete absorption time of adnexal mass were signifcantly shorter in the research group than in the control group [（27.56±8.01）d vs. （35.24±9.62） d, t=2.847, P=0.013; （35.44±13.28） d vs. （41.36±16.20） d, t=2.492, P=0.022]. The serum level of β-HCG, total TCM syndrome score, and diameter of adnexal mass were signifcantly decreased in both groups after the tratment （all P〈0.05）. The serum level of β-HCG, total TCM syndromes score, and diameter of adnexal mass were signifcantly lower in the research group than in the control group after the tratment [（351.46±102.53）U/L vs. （478.96±142.71）U/L, t=2.660, P=0.017; （5.72±1.93） vs. （7.24±1.85）, t=2.157, P=0.031; （0.58±0.06）cm vs. （1.04±0.08）cm, t=2.244, P=0.029]. The incidence of adverse reacti
作者
杨玉芳
Yang Yufang(Taixing Maternal and Child Health Care Hospital,Taixing 225400,China)
出处
《国际医药卫生导报》
2018年第22期3452-3456,共5页
International Medicine and Health Guidance News
关键词
输卵管妊娠
未破裂
中药汤剂
甲氨蝶呤
有效性
安全性
Tubal pregnancy
Unruptured
Traditional Chinese medicine decoction
Methotrexate
Effectiveness
Safety
